DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Real-time Bid/Ask 07:33:39 16/07/2024 pm IST | ||
| 2.33 EUR / 2.41 EUR | +3.95% |
|
| Current month | -2.15% | ||
| 1 month | -1.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 16/24/16 | 2.3 | +0.88% |
| 15/24/15 | 2.28 | -1.72% |
| 12/24/12 | 2.32 | -6.07% |
| 11/24/11 | 2.47 | +1.23% |
| 10/24/10 | 2.44 | -0.41% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 03:15 pm IST
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D7V |
| ISIN | DE000MG0D7V4 |
| Date issued | 18/03/2024 |
| Strike | 275 $ |
| Maturity | 20/12/2024 (157 Days) |
| Parity | 10 : 1 |
| Emission price | 2.09 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.58 € |
|---|---|
| Lowest since issue | 0.93 € |
| Spread | 0.15 € |
| Spread % | 6.07% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
280
USD
Average target price
365.3
USD
Spread / Average Target
+30.50%
- Stock Market
- Certificates
- Certificat
